Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Summary
This prediction ended on 11.01.26 with a price of €683.00. With a performance of -1.53%, the BUY prediction by Wells_Fargo___Compan finished with a loss. Wells_Fargo___Compan has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Dividends of €3.48 are taken into consideration when calculating the performance. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.867% | 1.867% | 6.250% |
| iShares Core DAX® | -3,81 % | -1,47 % | 6,06 % |
| iShares Nasdaq 100 | 0,49 % | 2,21 % | 12,68 % |
| iShares Nikkei 225® | -4,42 % | 4,97 % | 30,91 % |
| iShares S&P 500 | 0,25 % | 1,23 % | 9,37 % |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
30.04.25
30.04.26
04.03.26
Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
23.09.24
23.09.25
24.09.25
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
03.08.25

